AstraZeneca portfolio setback fuels speculation of Wallenberg-led M&A

AstraZeneca's recent clinical trial failure has weakened its research outlook, increasing market speculation regarding a potential acquisition or consolidation involving the Wallenberg family's investment interests. While the specific nature of a 'mega-deal' remains unconfirmed, the development signals a potential shift in the company's strategic direction under CEO Pascal Soriot.